TargeGen Acquired By Sanofi-aventis
socalTECH
JUNE 30, 2010
According to TargeGen, the deal's purchase price depends on the achievement of certain future milestones events. TargeGen's products are also potentially useful in treating certain forms of leukemia, lymphoma, other hematological malignancies and blood disorders. TargeGen had raised over $113M in venture funding from A.M.
140 
Let's personalize your content